Can Stem Cells Beat COVID-19: Advancing Stem Cells and Extracellular Vesicles Toward Mainstream Medicine for Lung Injuries Associated With SARS-CoV-2 Infections.
Coronavirus (2019-nCoV)
SARS-CoV-2
extracellular vesicles
lung injuries
stem cell
stem cell therapy
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
04
2020
accepted:
07
05
2020
entrez:
24
6
2020
pubmed:
24
6
2020
medline:
24
6
2020
Statut:
epublish
Résumé
A number of medicines are currently under investigation for the treatment of COVID-19 disease including anti-viral, anti-malarial, and anti-inflammatory agents. While these treatments can improve patient's recovery and survival, these therapeutic strategies do not lead to unequivocal restoration of the lung damage inflicted by this disease. Stem cell therapies and, more recently, their secreted extracellular vesicles (EVs), are emerging as new promising treatments, which could attenuate inflammation but also regenerate the lung damage caused by COVID-19. Stem cells exert their immunomodulatory, anti-oxidant, and reparative therapeutic effects likely through their EVs, and therefore, could be beneficial, alone or in combination with other therapeutic agents, in people with COVID-19. In this review article, we outline the mechanisms of cytokine storm and lung damage caused by SARS-CoV-2 virus leading to COVID-19 disease and how mesenchymal stem cells (MSCs) and their secreted EVs can be utilized to tackle this damage by harnessing their regenerative properties, which gives them potential enhanced clinical utility compared to other investigated pharmacological treatments. There are currently 17 clinical trials evaluating the therapeutic potential of MSCs for the treatment of COVID-19, the majority of which are administered intravenously with only one clinical trial testing MSC-derived exosomes via inhalation route. While we wait for the outcomes from these trials to be reported, here we emphasize opportunities and risks associated with these therapies, as well as delineate the major roadblocks to progressing these promising curative therapies toward mainstream treatment for COVID-19.
Identifiants
pubmed: 32574317
doi: 10.3389/fbioe.2020.00554
pmc: PMC7264098
doi:
Types de publication
Journal Article
Langues
eng
Pagination
554Informations de copyright
Copyright © 2020 Chrzanowski, Kim and McClements.
Références
Am J Respir Crit Care Med. 2020 May 15;201(10):1299-1300
pubmed: 32228035
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13724-9
pubmed: 20643923
Stem Cells Int. 2016;2016:3924858
pubmed: 27822228
Annu Rev Physiol. 2013;75:593-615
pubmed: 23398155
Intensive Care Med. 2020 Jun;46(6):1099-1102
pubmed: 32291463
Cell Transplant. 2019 Jan;28(1):36-46
pubmed: 30362373
Int J Infect Dis. 2016 Aug;49:129-33
pubmed: 27352628
Nature. 2020 Apr;580(7805):576-577
pubmed: 32346146
Am J Stem Cells. 2018 Oct 01;7(4):82-93
pubmed: 30510843
Proteomics. 2019 Sep;19(17):e1800166
pubmed: 31318160
Nat Mater. 2017 Dec;16(12):1233-1242
pubmed: 29115291
JAMA. 2020 Apr 13;:
pubmed: 32282022
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Methods Mol Biol. 2016;1516:243-255
pubmed: 27062596
Diabetes. 2008 Jul;57(7):1759-67
pubmed: 18586907
Biores Open Access. 2014 Aug 1;3(4):137-49
pubmed: 25126478
Anesthesiology. 2013 Apr;118(4):924-32
pubmed: 23377221
PLoS Med. 2006 Sep;3(9):e343
pubmed: 16968120
Int J Cell Biol. 2016;2016:6940283
pubmed: 27516776
Pediatr Int. 2019 Oct;61(10):945-950
pubmed: 31487104
J Immunol. 2017 May 15;198(10):4046-4053
pubmed: 28373583
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Periodontol 2000. 2013 Oct;63(1):198-216
pubmed: 23931061
Engineering (Beijing). 2020 Feb 28;:
pubmed: 32292627
Front Genet. 2017 Oct 25;8:161
pubmed: 29123544
J Cell Mol Med. 2018 Mar;22(3):1428-1442
pubmed: 29392844
Biomater Sci. 2017 Dec 19;6(1):60-78
pubmed: 29184934
Nat Commun. 2020 Feb 28;11(1):1064
pubmed: 32111836
Pharmacol Ther. 2015 Jul;151:8-15
pubmed: 25709098
FASEB J. 2019 Apr;33(4):5585-5598
pubmed: 30649987
Curr Hypertens Rep. 2020 Apr 14;22(5):37
pubmed: 32291521
Nat Mater. 2014 Jun;13(6):645-52
pubmed: 24633344
Nat Rev Drug Discov. 2020 May;19(5):305-306
pubmed: 32273591
Lancet Respir Med. 2015 Jan;3(1):24-32
pubmed: 25529339
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Aging Dis. 2020 Mar 9;11(2):216-228
pubmed: 32257537
J Aerosol Med Pulm Drug Deliv. 2016 Dec;29(6):514-524
pubmed: 27186789
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Nat Mater. 2016 Mar;15(3):326-34
pubmed: 26618884
Cell. 2006 Aug 25;126(4):677-89
pubmed: 16923388
Lancet Infect Dis. 2020 Apr;20(4):398-400
pubmed: 32113510
Rev Med Virol. 2018 May;28(3):e1977
pubmed: 29664167
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Respir Med. 2019 Feb;7(2):154-162
pubmed: 30455077
Cytotherapy. 2015 Jul;17(7):940-7
pubmed: 25869301
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
Am J Epidemiol. 2004 Feb 1;159(3):229-31
pubmed: 14742282
J Transl Med. 2020 Apr 14;18(1):164
pubmed: 32290839
Nature. 2018 May;557(7705):335-342
pubmed: 29769665